Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiki Nishimura

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
Cancers|November 13, 2013
Clinical Significance of CK19 Negative Breast CancerMamiko Fujisue, Reiki Nishimura, Yasuhiro Okumura, et al.
Molecular and Clinical Oncology|October 4, 2014
Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancerReiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama, et al.
Breast Cancer (Tokyo, Japan)|September 5, 2003
Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancerReiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, et al.
Breast Cancer (Tokyo, Japan)|August 5, 2011
Study on the state of implementation of HER2 testing and positive ratios in patients with breast cancer in the Kyushu-Okinawa region of JapanYasuaki Sagara, Yoshihiko Kamada, Yutaka Yamamoto, et al.
Oncology Letters|January 19, 2019
Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumorsNobuyuki Arima, Reiki Nishimura, Tomofumi Osako, et al.
Oncology|July 23, 2013
Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancerReiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama, et al.
Molecular and Clinical Oncology|March 21, 2014
Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)Reiki Nishimura, Nobuyuki Arima, Satoshi Toyoshima, et al.
Oncology Letters|September 12, 2012
Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracilAkihiko Osaki, Shoshu Mitsuyama, Jun-Ichi Kurebayashi, et al.
Anticancer Research|May 25, 2004
Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese studyToru Watanabe, Muneaki Sano, Shinji Ohno, et al.
Breast Cancer (Tokyo, Japan)|December 18, 2004
Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective studyJunichi Kurebayashi, Reiki Nishimura, Katsuhiro Tanaka, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Cancers|November 13, 2013
Clinical Significance of CK19 Negative Breast CancerMamiko Fujisue, Reiki Nishimura, Yasuhiro Okumura, et al.
Molecular and Clinical Oncology|October 4, 2014
Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancerReiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama, et al.
Breast Cancer (Tokyo, Japan)|September 5, 2003
Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancerReiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, et al.
Breast Cancer (Tokyo, Japan)|August 5, 2011
Study on the state of implementation of HER2 testing and positive ratios in patients with breast cancer in the Kyushu-Okinawa region of JapanYasuaki Sagara, Yoshihiko Kamada, Yutaka Yamamoto, et al.
Oncology Letters|January 19, 2019
Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumorsNobuyuki Arima, Reiki Nishimura, Tomofumi Osako, et al.
Oncology|July 23, 2013
Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancerReiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama, et al.
Molecular and Clinical Oncology|March 21, 2014
Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)Reiki Nishimura, Nobuyuki Arima, Satoshi Toyoshima, et al.
Oncology Letters|September 12, 2012
Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracilAkihiko Osaki, Shoshu Mitsuyama, Jun-Ichi Kurebayashi, et al.
Anticancer Research|May 25, 2004
Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese studyToru Watanabe, Muneaki Sano, Shinji Ohno, et al.
Breast Cancer (Tokyo, Japan)|December 18, 2004
Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective studyJunichi Kurebayashi, Reiki Nishimura, Katsuhiro Tanaka, et al.
Pageof 8